| Disease | THIS CLINICAL STUDY HAS BEEN DESIGNED TO EVALUATE THE EFFICACY OF AN EXTRACT OF PYGEUM AFRICANUM (TADENAN) (ROUSSEL-PHARMA) IN PATIENTS SUFFERING FROM PROSTATIC HYPERTROPHY OR CHRONIC PROSTATITIS. THE DRUG HAS BEEN ADMINISTERED TO 18 PATIENTS,
FOR 60 DAYS, AS DOUBLE OF STANDARD DOSAGE (200 MG/DIET PER OS, INSTEAD OF 100 MG/DIET). BECAUSE OF THE HIGH FREQUENCY OF ASSOCIATION OF SEXUAL DISORDERS WITH THOSE TWO PATOPOGIES, WE HAVE EXTENDED THE STUDY ALSO TO SEXUAL DISORDERS SELECTING
PATIENTS SUFFERING FROM PROSTATIC HYPERTROPHY OR CHRONIC PROSTATITIS AND, CONTEMPORARELY, FROM SEXUAL DISTURBANCES. NO SIDE EFFECTS HAVE BEEN OBSERVED DURING THE TREATMENT. THE URINARY DISTURBANCES HAVE BEEN EVALUATED BY ANAMNESYS AND PROSTATIC
TRANSRECTAL ECOGRAPHY; SEXUAL DISORDERS HAVE BEEN EVALUATED BY ANAMNESYS AND NOCTURNAL PENILE TUMESCENCE AND RIGIDITY (NPTR) MONITORING. FURTHERMORE, DOSAGE OF SERUM LEVELS OF THE HORMONES LH, FSH, PROLACTIN, 17-BETA-ESTRADIOL AND TESTOSTERONE
HAS BEEN PERFORMED BEFORE AND AFTER THERAPHY. PYGEUM AFRICANUM EXTRACT ADMINISTRATION IMPROVED ALL THE URINARY PARAMETERS WE INVESTIGATED; PROSTATIC ECOGRAPHY RELEAVED RIDUCTION OF PERIURETRAL ADEMA.
ALSO AN IMPROVEMENT OF SEXUAL BEHAVIOR HAS BEEN OBTAINED; NO SIGNIFICANT DIFFERENCES BETWEEN SERUM HORMONAL LEVELS BEFORE AND AFTER THERAPY WERE FOUND, AS WELL AS FOR NPTR.
A COMMERCIAL PRODUCT, TADENAN, WAS USED. |